Myo-Inositol for Ocd Support

Research suggests that myo-inositol may offer modest benefits for OCD symptoms, with the most direct support coming from a small double-blind crossover randomized controlled trial that found significant symptom reduction compared to placebo, and several narrative and systematic reviews that characterize the evidence as preliminary but encouraging. Studies indicate that inositol's potential effects may be linked to its role in cellular signaling pathways involving serotonin-coupled receptors, which also underlie the action of commonly prescribed OCD medications, and animal model research broadly supports this mechanistic rationale. However, the overall evidence base is limited in important ways: a 2014 meta-analysis pooling data from multiple trials found no statistically significant effect of inositol on obsessive-compulsive symptoms, and a 2022 systematic review found that while mitochondria-influencing compounds as a class outperformed placebo, inositol individually did not show a strong signal compared to N-acetylcysteine. Taken together, the research remains inconclusive — existing studies are small, methodologically variable, and insufficiently powered to support firm conclusions, and experts across multiple reviews have consistently called for larger, well-designed trials before myo-inositol can be confidently characterized as an effective intervention for OCD.